Skip to content

Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00751452
Enrollment
30
Registered
2008-09-12
Start date
2008-04-30
Completion date
2009-09-30
Last updated
2011-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Disease

Keywords

Children, Allogeneic bone marrow transplantation, Intestinal damage, Citrulline, Graft versus Host Disease, 0 to 18 years old

Brief summary

determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Detailed description

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days). Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Interventions

None listed

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* 0 to 18 years * allogeneic bone marrow transplantation for malignant or benign disease * affiliation to French sécurité sociale * parent's consent

Exclusion criteria

* severe gastro-intestinal involvement before transplant * previous digestive surgery

Design outcomes

Primary

MeasureTime frame
Citrullinemia (weekly)weekly

Secondary

MeasureTime frame
Gastro-intestinal complications in children following allogeneic bone marrow transplantationfollowing allogenic bone marrow transplantation

Countries

France

Contacts

Primary ContactLacarin Patrick
placarin@chu-clermontferrand.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026